Edwards Lifesciences Corp
NYSE: EW·Irvine, California·CIK 0001099800
- Price
- $107.11
- Base IV
- $61.20
Valuation snapshot
At $107.11, the price is above even our bull case of $84.86.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $61.20
- 57% of the price · range $38.90–$84.86
- Price vs base case
- 75% above
- $107.11 against $61.20
- Base case · our researched forecast, 2026-11-05See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has risen 7.8% since this valuation was struck on 2026-11-05, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $38.90 to bull $84.86. Values per share.
Price against each value
- Bear case
- $38.90
- Price 175% above
- No growth
- …
- —
- Base case
- $61.20
- Price 75% above
What does Edwards Lifesciences do?
Edwards Lifesciences provides surgical and transcatheter heart valves and repair systems to help clinicians treat patients with structural heart diseases and valvular disorders.
It brought in $6.7B of sales in the 12 months to Sep 2026.
Led by Bernard J. Zovighian, Chief Executive Officer since 2023. Our Leaders | Edwards Lifesciences
- Industry
- Healthcare
- Based in
- Irvine, California
- Trades on
- NYSE as EW
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 15¢ was left as profit after every cost, interest and tax. The biggest cost is sales, marketing and admin, 34¢ of every dollar.
- Making what it sells22¢
- Research and development16¢
- Sales, marketing and admin34¢
- Everything else it takes to operate6¢
- Tax7¢
- Left as profit15¢
- Other items after tax came back in+1¢
Who pays Edwards Lifesciences, and for what?
Edwards makes devices that repair or replace heart valves, using both surgery and catheter-based procedures. It earns revenue by selling these products to hospitals and other health care providers around the world.
Its customers are hospitals and other health care providers, including physicians, hospital purchasing groups, and health systems.
Transcatheter Aortic Valve Replacement (TAVR)
74%Catheter-delivered valves that replace a diseased aortic valve.
Edwards SAPIEN 3 Ultra RESILIA transcatheter heart valveImage: Edwards Lifesciences Transcatheter Mitral and Tricuspid Therapies (TMTT)
9%Catheter-based systems to repair or replace mitral and tricuspid valves.
Edwards EVOQUE transcatheter tricuspid valve replacement systemImage: Edwards Lifesciences Surgical Structural Heart
17%Tissue heart valves and related products used in surgical procedures.
Edwards INSPIRIS RESILIA surgical aortic tissue heart valveImage: Edwards Lifesciences
Where its work physically happens, beyond headquarters:
- Cartago manufacturing facilities — Cartago, Costa Rica. Edwards identifies Cartago as a major manufacturing location, making its production capacity part of the supply network for its structural heart products.
- Singapore manufacturing facilities — Singapore, Singapore. The Singapore facilities combine manufacturing and distribution, and Edwards says it has doubled their size with additional cleanrooms.
- Limerick manufacturing plant — Limerick, Ireland. Edwards identifies its Limerick plant as a manufacturing facility, providing production capacity in Europe.
- Draper manufacturing site — Draper, United States. Edwards lists Draper among its major manufacturing properties, making it a material part of its U.S. production footprint.
- Moncada manufacturing plant — Moncada, Spain. The plant was under construction in the 2025 Form 10-K and is planned to add capacity for structural heart medical devices when operational.
How is the business doing?
Sales grew from $4.4B in 2020 to $6.1B in 2025, about 7% a year.
Running the business leaves about 22¢ of each sales dollar as operating profit, about the same as 20¢ in 2020.
After paying for its upkeep and new investment, it had $1.4B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Edwards says it aims to provide innovative solutions for people with cardiovascular disease and improve quality of life.
“We are dedicated to providing innovative solutions for people fighting cardiovascular disease.”
Who is responsible for the plan?
- Bernard J. ZovighianChief Executive Officer
Oversees global operations, corporate strategy, and organization-wide business activities as Chief Executive Officer. Leads the company in developing and commercializing medical technologies and therapies for structural heart disease.
- Daveen ChopraCorporate Vice President, Transcatheter Mitral and Tricuspid Therapies
Oversees the global clinical evaluation, development, and commercial operations of the Transcatheter Mitral and Tricuspid Therapies business. Drives commercial sales and adoption of catheter-based repair and replacement technologies for mitral and tricuspid valve disease.
- Todd J. BrintonCorporate Vice President, Advanced Technology and Chief Scientific Officer
Oversees the company's advanced technology organization, research and development programs, and early-stage pipeline innovations. Develops early-stage cardiovascular device technologies that expand Edwards' structural heart product pipeline.
Roles checked November 14, 2026.
What management says it is working on now:
Develop heart valve therapies
Management says it is investing in new therapies and clinical evidence for aortic, mitral, and tricuspid valve disease.
Edwards Lifesciences 2025 Form 10-KExpand treatment options
The company says it aims to address structural heart conditions beyond valve disease, including heart failure.
Edwards Lifesciences 2025 Form 10-KBuild clinical evidence and patient access
Management emphasizes evidence on patient outcomes and working with clinicians and health care stakeholders to support approvals and adoption.
Edwards Lifesciences Reports Second Quarter ResultsGrow TMTT
Management points to its repair and replacement portfolio, including PASCAL, EVOQUE, and SAPIEN M3, as part of its growth plans.
Edwards Lifesciences Reports Second Quarter Results
- Total company sales growth, 2026
- 10% to 11% at constant currency
- Edwards Lifesciences Reports Second Quarter Results
- TAVR sales growth, 2026
- 8% to 9% at constant currency
- Edwards Lifesciences Reports Second Quarter Results
What's changing right now?
Growth is slowing. In Q3 2026 it sold 10% more than a year earlier. The year before, quarters averaged 15%.
Its operating margin is narrower than a year ago: 17¢ per sales dollar, against 20¢.
Since Oct 2026 the share price has risen 13%, from $94.44 to $107.11.
Recently
June 30, 2026
TMTT quarterly sales changed to $198.6M
Edwards Q2 2026 results, product-group tableJune 30, 2026
TAVR quarterly sales changed to $1.3B
Edwards Q2 2026 results, product-group tableDecember 31, 2024
TMTT Net Sales (Annual) changed to $352.1M
Edwards Lifesciences 2024 Form 10-K Item 7 Product Group Sales
Coming up
November 2, 2026
Investor event at the TCT scientific symposium
The company plans an investor event with physicians and management, including a live question-and-answer session.
Edwards Lifesciences to Host Investor Event in Conjunction With TCTNovember 4, 2026
Third-quarter results and outlook
Edwards plans to report results for the quarter ended September 30 and discuss them on a conference call.
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026December 2026
2027 and longer-term guidance
The company says it expects to provide 2027 and longer-term guidance at its investor conference.
Edwards Lifesciences Comments on TAVR National Coverage Decision
Our own estimate moved too: the base case went from $45.69 to $61.20 a share between our last two valuations. The biggest reason: TMTT Net Sales (Annual) moved from an unreported prior value to $352.1M, as reported in Edwards Lifesciences 2024 Form 10-K Item 7 Product Group Sales.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Competition and changing treatment options
Rivals and new treatments could make Edwards products less attractive. The company also says hospitals may have limited staff and procedure capacity to support all available therapies.
From the company's own filingsWould hit how fast sales growEdwards Lifesciences 2025 Form 10-K
Product development and clinical results
New products and uses require development, clinical studies, and regulatory review. Delays or disappointing results could slow approvals and sales.
From the company's own filingsWould hit how fast sales growEdwards Lifesciences 2025 Form 10-K
Manufacturing and supply interruptions
Production problems, quality issues, or a disruption at a supplier could delay products, lead to recalls, or raise costs. Some supplies come from single sources.
From the company's own filingsWould hit how fast sales growEdwards Lifesciences 2025 Form 10-K
Regulatory approval and reimbursement
Regulators can delay or restrict product sales, while public or private payers may limit coverage or payment. Either could reduce hospitals’ ability or willingness to use the products.
From the company's own filingsWould hit how fast sales growEdwards Lifesciences 2025 Form 10-K
Pricing pressure from large purchasers
Hospitals and purchasing groups are consolidating, which can increase their negotiating power and put pressure on product prices.
From the company's own filingsWould hit how much of each sale it keepsEdwards Lifesciences 2025 Form 10-K
International and economic uncertainty
Tariffs, currency movements, political changes, or higher costs could disrupt supply, reduce sales, or affect margins across the company’s global operations.
From the company's own filingsWould hit how much of each sale it keepsEdwards Lifesciences 2025 Form 10-K
Annual revenue growth was limited to 0.0332 in 2024 and negative 0.0218 in 2023 during structural portfolio transitions and currency swings.
From our researchWould hit how fast sales growEdwards Lifesciences Consolidated Financial Statements
Is it a good business?
From 2017 to 2025 it earned between 14% and 30% on the capital invested in it, a median of 22%. Its cost of capital in the latest valuation is 8.7%; returns were above it in every one of the 9 years.
From 2016 to 2025 it earned between 10% and 42% on its shareholders' equity, a median of 22%.
Over 9 years its operating margin ranged from 20¢ to 32¢ per sales dollar, a median of 26¢. Gross margin ran from 73¢ to 80¢.
Cost of capital 8.7%
It bought back shares: the count fell 1.4% in a year, so each remaining share owns a slightly bigger slice.
It holds $2.5B more in cash than it owes.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $107.11. Our put its value between $38.90 and $84.86, with $61.20 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $38.90
This cautious scenario assumes that hospital procedure limits and intense competition slow down heart valve sales gains while price cuts squeeze corporate profits.
Base case, $61.20
This balanced scenario assumes steady high-single-digit sales gains driven by established heart valves and new catheter therapies while underlying business profitability remains solid.
Bull case, $84.86
This optimistic scenario assumes double-digit sales growth accelerates as breakthrough treatments for leaky mitral and tricuspid valves win wide global adoption and boost company profitability.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 75%
For Edwards Lifesciences to be worth today's $107.11, sales would need to grow about 23.2% a year. We assume 8.5%. Over the last 5 years, sales grew 5.6% a year.
Or, if sales grow 8.5% as we assume, the price works with a profit margin of 51.5% (we assume 28.5%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 23.2% a year?
Try your own numbersWe're moderately sure of this range: it scores 71 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $61.20 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average8.5%
- Operating margin28.5%
- Long-term growth rate3.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$61.20 -42.9%

